Meeting
2022 ASCO Annual Meeting
Landscape of fibroblast growth factor receptor (FGFR) genomic alterations (GA) in urothelial bladder cancer (UBC).
Authors
Maroun Bou Zerdan
Cleveland Clinic Florida, Weston, FL
Maroun Bou Zerdan , Gennady Bratslavsky , Joseph M Jacob , Richard S.P. Huang , Oleksandr Kravtsov , Vamsi Parimi , Douglas I. Lin , Ryon Graf , Natalie Danziger , Jeffrey S. Ross , Hanan Goldberg , Alina Basnet
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Urothelial Cancer - Advanced/Metastatic Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4568)
DOI
10.1200/JCO.2022.40.16_suppl.4568
Abstract #
4568
Poster Bd #
59
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Penile squamous cell carcinoma (PSCC) with elevated tumor mutational burden (TMB): A genomic landscape study.
First Author: Rebecca A Sager
Poster
2022 ASCO Genitourinary Cancers Symposium
Impact of PD-L1 expression on conventional urothelial bladder carcinoma (UBC) genomic alteration (GA) profile.
First Author: Petros Grivas
Poster
2022 ASCO Genitourinary Cancers Symposium
Expanding the use of targeted therapy for urothelial bladder cancer (UBC): Non-FGFR3 receptor tyrosine kinase (RTK) gene rearrangements (ReAr) and fusions (fus).
First Author: Andrea Necchi
Poster
2024 ASCO Genitourinary Cancers Symposium
Genomic correlates of response and resistance to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting.
First Author: Nikhil Pramod